scholarly journals An Orally Administrated Hyaluronan Functionalized Polymeric Hybrid Nanoparticle System for Colon-Specific Drug Delivery

Nanomaterials ◽  
2019 ◽  
Vol 9 (9) ◽  
pp. 1246 ◽  
Author(s):  
Niranjan G. Kotla ◽  
Orla Burke ◽  
Abhay Pandit ◽  
Yury Rochev
Keyword(s):  
Drug Delivery ◽  
Local Drug Delivery ◽  
Cellular Interaction ◽  
Drug Side Effects ◽  
Hybrid Particles ◽  
Disease Site ◽  
Delivery Platform ◽  
Nanoparticle System ◽  
Inflammatory Bowel ◽  
Ht 29

There is a pressing clinical need for advanced colon-specific local drug delivery systems that can provide major advantages in treating diseases associated with the colon, such as inflammatory bowel disease (IBD) and colon cancer. A precise colon targeted drug delivery platform is expected to reduce drug side effects and increase the therapeutic response at the intended disease site locally. In this study, we report the fabrication of hyaluronan (HA) functionalized polymeric hybrid nanoparticulate system (Cur-HA NPs) by using curcumin as a model fluorescent drug. The Cur-HA NPs were about 200–300 nm in size, −51.3 mV overall surface charge after HA functionalization, with 56.0% drug released after 72 h in simulated gastrointestinal fluids. The Cur-HA NPs did not exhibit any cytotoxicity by AlamarBlue, PicoGreen and Live/Dead assays. Following the Cur-HA NPs use on HT-29 monolayer cell cultures demonstrating, the efficacy of HA functionalization increases cellular interaction, uptake when compared to uncoated nanoparticulate system. These findings indicate that HA functionalized nano-hybrid particles are effective in delivering drugs orally to the lower gastrointestinal tract (GIT) in order to treat local colonic diseases.

scholarly journals Advances in Biomimetic Nanoparticles for Targeted Cancer Therapy and Diagnosis

Molecules ◽  
2021 ◽  
Vol 26 (16) ◽  
pp. 5052
Author(s):  
Chaw Yee Beh ◽  
Ray Putra Prajnamitra ◽  
Li-Lun Chen ◽  
Patrick Ching-Ho Hsieh
Keyword(s):  
Drug Delivery ◽  
Immune System ◽  
Rapid Development ◽  
Clinical Stage ◽  
Tumour Microenvironment ◽  
Malignant Tumours ◽  
Biomimetic Nanoparticles ◽  
Recent Developments ◽  
Disease Site ◽  
Delivery Platform

Biomimetic nanoparticles have recently emerged as a novel drug delivery platform to improve drug biocompatibility and specificity at the desired disease site, especially the tumour microenvironment. Conventional nanoparticles often encounter rapid clearance by the immune system and have poor drug-targeting effects. The rapid development of nanotechnology provides an opportunity to integrate different types of biomaterials onto the surface of nanoparticles, which enables them to mimic the natural biological features and functions of the cells. This mimicry strategy favours the escape of biomimetic nanoparticles from clearance by the immune system and reduces potential toxic side effects. Despite the rapid development in this field, not much has progressed to the clinical stage. Thus, there is an urgent need to develop biomimetic-based nanomedicine to produce a highly specific and effective drug delivery system, especially for malignant tumours, which can be used for clinical purposes. Here, the recent developments for various types of biomimetic nanoparticles are discussed, along with their applications for cancer imaging and treatments.

scholarly journals An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease

2015 ◽  
Vol 7 (300) ◽  
pp. 300ra128-300ra128 ◽  
Author(s):  
Sufeng Zhang ◽  
Joerg Ermann ◽  
Marc D. Succi ◽  
Allen Zhou ◽  
Matthew J. Hamilton ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Local Drug Delivery ◽  
Inflammatory Bowel ◽  
Inflammation Targeting

Mo1700 Targeted Topical Therapy to Treat Inflammatory Bowel Disease Using a Novel Thermosensitive Drug Delivery Platform

2015 ◽  
Vol 148 (4) ◽  
pp. S-689
Author(s):  
Sidhartha R. Sinha ◽  
Linh P. Nguyen ◽  
Mohammed Inayathullah ◽  
Andrey Malkovskiy ◽  
Frezghi Habte ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Topical Therapy ◽  
Delivery Platform ◽  
Inflammatory Bowel

scholarly journals Polymer-free hydrogel made of lipid nanocapsules, as a local drug delivery platform

2021 ◽  
pp. 112188
Author(s):  
Marion Pitorre ◽  
Claire Gazaille ◽  
Le Thuy Trang Pham ◽  
Karolina Frankova ◽  
Jérôme Béjaud ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Local Drug Delivery ◽  
Lipid Nanocapsules ◽  
Delivery Platform

scholarly journals Inflammation specific targeted carriers for local drug delivery to inflammatory bowel disease

Biomaterials ◽  
2022 ◽  
pp. 121364
Author(s):  
Niranjan G. Kotla ◽  
Rajbir Singh ◽  
Becca V. Baby ◽  
Swetha Rasala ◽  
Jawad Rasool ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Local Drug Delivery ◽  
Inflammatory Bowel

scholarly journals Therapeutic effects of local drug delivery systems - PerioChip® in the treatment of periodontal disease

2014 ◽  
Vol 60 (01) ◽  
pp. 3-8
Author(s):  
Liljana Bogdanovska ◽  
Sahmedin Sali ◽  
Mirjana Popovska ◽  
Ilijana Muratovska ◽  
Aneta Dimitrovska ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Periodontal Disease ◽  
Drug Delivery Systems ◽  
Disease Recurrence ◽  
Delivery Systems ◽  
Periodontal Treatment ◽  
Local Drug Delivery ◽  
Therapeutic Effects ◽  
Disease Site ◽  
Low Incidence

The primary goal of periodontal treatment is to stop periodontal disease progression and reduce future risks in disease recurrence. In order to overcome the limitations of the conventional treatment, controlled drug delivery systems for application in periodontal pockets have been developed. Their use offers several advantages: the therapeutic agent is targeted directly to the disease site and concentrations are 10-100 folds higher than the concentrations achieved by systemic administration, with low incidence of side effects. The PerioChip® is as local controlled-release biodegradable delivery system containing chlorhexidine digluconate. Several multicenter clinical trials have shown that the application of the PerioChip® in periodontal pockets as adjunct to the conventional periodontal treatment significantly improved the clinical parameters. In this article, the results from controlled clinical studies aimed to evaluate the clinical and microbiological efficacy of the PerioChip®, are discussed.

scholarly journals P-selectin is a nanotherapeutic delivery target in the tumor microenvironment

2016 ◽  
Vol 8 (345) ◽  
pp. 345ra87-345ra87 ◽  
Author(s):  
Yosi Shamay ◽  
Moshe Elkabets ◽  
Hongyan Li ◽  
Janki Shah ◽  
Samuel Brook ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Tumor Microenvironment ◽  
Kinase Inhibitor ◽  
Mitogen Activated Protein Kinase ◽  
Drug Classes ◽  
Mitogen Activated Protein ◽  
Tumor Endothelium ◽  
Disease Site ◽  
Delivery Platform ◽  
Potential Strategy

Disseminated tumors are poorly accessible to nanoscale drug delivery systems because of the vascular barrier, which attenuates extravasation at the tumor site. We investigated P-selectin, a molecule expressed on activated vasculature that facilitates metastasis by arresting tumor cells at the endothelium, for its potential to target metastases by arresting nanomedicines at the tumor endothelium. We found that P-selectin is expressed on cancer cells in many human tumors. To develop a targeted drug delivery platform, we used a fucosylated polysaccharide with nanomolar affinity to P-selectin. The nanoparticles targeted the tumor microenvironment to localize chemotherapeutics and a targeted MEK (mitogen-activated protein kinase kinase) inhibitor at tumor sites in both primary and metastatic models, resulting in superior antitumor efficacy. In tumors devoid of P-selectin, we found that ionizing radiation guided the nanoparticles to the disease site by inducing P-selectin expression. Radiation concomitantly produced an abscopal-like phenomenon wherein P-selectin appeared in unirradiated tumor vasculature, suggesting a potential strategy to target disparate drug classes to almost any tumor.

Modern Possibilities of Organ-Preserving Treatment in Children with Intraocular Retinoblastoma

2018 ◽  
Vol 5 (3) ◽  
pp. 175-187 ◽  
Author(s):  
O. V. Gorovtsova ◽  
T. L. Ushakova ◽  
V. G. Polyakov
Keyword(s):  
Drug Delivery ◽  
Survival Rate ◽  
Cancer Therapy ◽  
Neoadjuvant Chemotherapy ◽  
Patient Survival ◽  
Focal Therapy ◽  
Local Drug Delivery ◽  
Large Size ◽  
Intraocular Retinoblastoma

Retinoblastoma is one of highly curable diseases; today the total 5-year survival rate in patients with retinoblastoma exceeds 95%. The article summarizes the current world experience on treatment of patients with intraocular retinoblastoma. The treating skills of intraocular malignant tumor in children are a balance between the patient’s life and the preservation of an eye and its visual functions. The complex and challenging task is the treatment of common intraocular retinoblastoma groups «C», «D», «E» when the large size or localization of the tumor does not allow performing the local (focal) destruction of the tumor. As a rule, in such cases neoadjuvant chemotherapy (CT) is performed at the first stage in order to reduce the size of the tumor for further focal therapy. However, the analysed data on the effectiveness of neoadjuvant CT in combination with focal or radiotherapy demonstrated the limited possibilities of the proposed therapy. Local drug delivery in cancer therapy became a real breakthrough in the organ-preserving treatment of children with large intraocular retinoblastoma. The most widely used current methods of local drug delivery are intravitreal (IVitC) and selective intra-arterial chemotherapy (SIAC) as monotherapy or in combination with neoadjuvant CT and focal therapy which significantly increased the percentage of preserved eyes without radiotherapy administration or damage to the patient survival. The review discusses the different IVitC and SIAC techniques, chemotherapy schemes, dosages of chemotherapy, immediate and long-term complications of treatment.

Sign in / Sign up

Export Citation Format

Share Document